Bajaj Healthcare secures DCGI approval to manufacture Pimavanserin in India
Bajaj Healthcare Limited has received approval from the Drug Controller General of India (DCGI) to manufacture both the Active Pharmaceutical Ingredient (API) and Drug Formulation of Pimavanserin, a 34 mg capsule used to treat hallucinations and delusions …